Home Newsfeeds Keybanc Downgrades Sherwin-Williams to Sector Weight

Keybanc Downgrades Sherwin-Williams to Sector Weight

Keybanc analyst Kenneth Zener downgrades Sherwin-Williams (NYSE:SHW) from Overweight to Sector Weight.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Keybanc analyst Kenneth Zener downgrades Sherwin-Williams (NYSE:SHW) from Overweight to Sector Weight.

Citigroup Maintains Neutral on Sensata Technologies, Lowers Price Target to $42

By Benzinga Newsdesk

October 26, 10:55 AM

Citigroup analyst Jim Suva maintains Sensata Technologies (NYSE:ST) with a Neutral and lowers the price target from $45 to $42.

Brenmiller Energy Ltd. Announces Pricing Of $4M Offering With A U.S. Based Institutional Investor For The Issuance And Sale Of 888,890 Units, At A Price Per Unit Of $4.50

By Benzinga Newsdesk

January 23, 9:14 AM

Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy", the "Company") (NASDAQ:BNRG), a global leader in thermal energy storage (TES), announced today it entered into a securities purchase agreement with a U.S. based

BNRG

Meta Goes Aggressive On VR Despite Regulatory Hindrances; Scoops Another VR Startup For Undisclosed Terms

By Anusuya Lahiri

September 6, 8:00 AM

Facebook parent Meta Platforms Inc (NASDAQ:META) scooped Lofelt, a Berlin startup, the Wall Street Journal reports. The financial terms of the…

Recap: Phathom Pharmaceuticals Q2 Earnings

By Benzinga Insights

August 2, 9:16 AM

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

PHAT

Keybanc Downgrades Sherwin-Williams to Sector Weight

Related Posts

Citigroup Maintains Neutral on Sensata Technologies, Lowers Price Target to $42

Brenmiller Energy Ltd. Announces Pricing Of $4M Offering With A U.S. Based Institutional Investor For The Issuance And Sale Of 888,890 Units, At A Price Per Unit Of $4.50

Meta Goes Aggressive On VR Despite Regulatory Hindrances; Scoops Another VR Startup For Undisclosed Terms

Recap: Phathom Pharmaceuticals Q2 Earnings